• Subscribe
  • Register for free Content
  • Cart
  • Login
  • Browse by Topic
    • 13 Reasons Why
    • Abstinence
    • Acamprosate
    • Addiction
    • Addiction Treatment
    • Addyi
    • Adhansia XR
    • ADHD
    • Adherence
    • Adjunct treatment
    • adolescents
    • Adult ADHD
    • Adverse Childhood Experiences (ACES)
    • Affordable Care Act (ACA)
    • Agitation
    • air pollution
    • Akathisia
    • Alcohol
    • Alcohol Use
    • Alcohol use disorder
    • Alcoholism
    • Alpha Agonists
    • Alternative treatments
    • Amantadine
    • amphetamine
    • Amphetamines
    • Anorexia Nervosa
    • Antidepressant
    • Antidepressant Augmentation
    • Antidepressants
    • Antipsychotic
    • Antipsychotics
    • Anxiety
    • Anxiety Disorder
    • APA CE Post-Test
    • Aripiprazole
    • ArModafinil
    • Asenapine
    • Assessment
    • asthma
    • atamoxetine
    • attention
    • Attention Deficit Hyperactivity Disorder
    • Atypical Antipsychotics
    • Austedo
    • Autism
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder autism spectrum disorder
    • Behavior therapy
    • Behavioral addiction
    • Behavioral therapy
    • Behavioral treatment
    • Belsomra
    • Benzodiazepine
    • Benzodiazepines
    • Beta-blockers
    • Billing
    • Bipolar Depression
    • Bipolar Disorder
    • Bipolar II
    • Board Certification
    • Borderline Personality Disorder
    • BPD
    • Brain Devices
    • Brief psychotherapy
    • Brief Strategic Family Therapy (BFST)
    • Bulimia Nervosa
    • Bullying
    • Buprenorphine
    • Bupropion
    • Buspirone
    • C-Reactive Protein
    • Caffeine
    • CAM Treatments
    • Cannabidiol
    • Cannabis
    • Caplyta
    • Carbamazepine
    • Cardiovascular
    • Cariprazine
    • CATIE
    • Chantix
    • Child and adolescent
    • Child Psychiatry
    • Child Psychiatry
    • children
    • Chokroverty
    • Chromosomal Microarray
    • Citalopram
    • Clinical practice
    • Clozapine
    • CME Post-Test
    • Co-occurring disorders
    • Cocaine
    • Cognition
    • Cognitive Behavioral Therapy
    • Cognitive Decline
    • cognitive impact
    • Cognitive Rehabilitation Therapy (CRT)
    • Collaborative care
    • Combination treatment
    • community trauma
    • Comorbidity
    • Complementary treatments
    • Complimentary treatments
    • Computer addiction
    • Computers in Psychiatric Practice
    • Conduct Disorder
    • Confidentiality
    • Connect
    • Connection
    • Connections
    • Contagion
    • Coronavirus
    • Cosmetic pharmacology
    • COVID-19
    • COVID19
    • Creativity
    • Crime
    • Criminal behavior
    • Crisis intervention
    • Crocus Sativus
    • CRP
    • Cultural Competence
    • Culture
    • custody agreement
    • Cymbalta
    • CYP2C19
    • CYP2D6
    • Dayvigo
    • Deliberate foreign body ingestion
    • Delusional Disorder
    • Dementia
    • Deplin
    • Deprescribing
    • Depression
    • Depressive Disorder
    • Detoxification
    • Deutetrabenazine
    • DFBI
    • Diagnosis
    • Diagnostic Testing
    • Disaster
    • Disparities
    • Diversity
    • Divorce
    • Dopamine
    • Dosage Timing
    • DSM
    • Dual diagnosis
    • Duloxetine
    • Dyslexia
    • Dysregulation
    • E-Cigarettes
    • Eating Disorders
    • eCigarettes
    • ECT
    • Effexor
    • efficacy
    • electronic use
    • emergent suicidality
    • Emotional dysregulation
    • End of Life Care
    • Engagement
    • Escitalopram
    • Esketamine
    • Eszopiclone
    • eTNS
    • Exercise
    • Existing marijuana
    • expressed emotion
    • extended-release
    • Falls
    • Family Separation
    • Fast-acting
    • FDA Warnings
    • Female hypoactive sexual desire disorder
    • Female Issues in Psychiatry
    • Fluoxetine
    • Folate
    • Folic Acid
    • Fragile X
    • Free Articles
    • gabapentin
    • GAD
    • Gastroenterology
    • Gender
    • Gender & Sexuality
    • Gender Diverse
    • Gender Dysphoria
    • Gender Identity
    • Generalized Anxiety Disorder
    • Generics
    • GeneSight
    • Genetic Testing
    • Genetics and Psychiatry
    • Geriatric Psychiatry
    • Ginkgo
    • Guanfacine
    • Hair loss
    • Harm reduction
    • Head Trauma
    • Health Apps
    • Heart health
    • Heart rate
    • Hepatitis
    • Heroin
    • HIPAA
    • Histamine
    • HIV
    • Hormone Replacement Therapy
    • Hypnotics
    • Hypomania
    • Incarceration
    • Inflammation
    • Ingrezza
    • Inpatient Psychiatry
    • inquiry
    • Insomnia
    • Insurance
    • Internet
    • Interpreter
    • Intervention
    • Intra-nasal
    • Irritability
    • Keppra
    • Ketamine
    • l-methylfolate
    • Laboratory Testing in Psychiatry
    • Lamictal
    • Lamotrigine
    • Language
    • Lavender
    • Learning & Developmental Disabilities
    • Least Restrictive Environment
    • Legal issues
    • Lemborexant
    • Levetiracetam
    • LGBT
    • LGBTQ+
    • Life coaching
    • Life expectancy
    • Light and Dark Therapy
    • Light therapy
    • Lightbox
    • Literacy
    • Lithium
    • Longevity
    • Low libido
    • Lumateperone
    • Lurasidone
    • Lyrica
    • Malingering
    • Management
    • Mania
    • Mania on Antidepressants
    • MAOIs
    • Marijuana
    • Media
    • Medical Comorbidities
    • Medication
    • Medication adherence
    • medications
    • Melatonin
    • Meta-analysis
    • Metabolic syndrome
    • Metformin
    • Methadone
    • methylfolate
    • methylphenidate
    • Micronutrients
    • Mind-Gut Connection
    • Mindfulness
    • Minority
    • Mirtazapine
    • Mixed Features
    • Modafinil
    • Mood stabilizer
    • Mood Stabilizers
    • Mortality
    • Motivational Interviewing
    • MTA
    • MTHFR
    • Naloxone
    • Naltrexone
    • Narcolepsy
    • Natural Medications
    • natural treatments
    • Negative Symptoms
    • Netflix
    • Neurology
    • Neuroscience in Psychiatry
    • Neurotoxicity
    • New York
    • News of Note
    • Nightmares
    • Norepinephrine
    • Nortriptyline
    • Novel Medications
    • Nuedexta
    • Nuplazid
    • Nutrition
    • Nuvigil
    • Obesity
    • observational study
    • Obsessive Compulsive Disorder
    • Obsessive compulsive disorder/OCD
    • OCD
    • olanzapine
    • online therapy
    • Opioid epidemic
    • Opioid Use Disorder
    • Opioids
    • Oral Contraceptives
    • Orexin
    • Orthostasis
    • Outcomes
    • Outpatient
    • Overdose
    • Oxcarbazepine
    • Pain
    • pandemic
    • Panic Disorder
    • Parenting Strategies
    • Parkinson’s
    • Parkinson’s Disease
    • Paroxetine
    • Particulate matter
    • Patch
    • Patient relationship
    • pediatric
    • Perseveration
    • Perseverative Behavior
    • Personality Disorders
    • Pharmaceutical Industry
    • Pharmacogenomics
    • Pharmacology
    • Pharmacology Tips
    • Pharmacy
    • phonemic awareness
    • Phonics
    • Physician assisted suicide
    • Pica
    • PICOT
    • Pimozide
    • Pitolisant
    • Podcast
    • polypharmacy
    • Postpartum Depression
    • Potency
    • Practice Tools and Tips
    • Practice Tools and Tips
    • Pramipexole
    • Prazosin
    • Pregabalin
    • Pregnancy
    • prescribing patterns
    • Prescription costs
    • Prevention
    • Primary care
    • Prison
    • Prodrome
    • Prolonged exposure
    • Promotoras
    • Pronouns
    • Provigil
    • Prozac
    • pseudobulbar affect
    • Psychiatric interviewing
    • Psychological First Aide
    • Psychopharm Myths
    • Psychopharmacology
    • Psychopharmacology Tips
    • Psychosis
    • Psychotherapy
    • Psychotherapy
    • Psychotic Depression
    • Psychotropic medication
    • PTSD
    • Public health
    • Quality of care
    • quality of life
    • Quetiapine
    • Race
    • Randomized controlled trial
    • rapid naming
    • Reading
    • Reading disorder
    • Reading Disorders
    • Reading remediation
    • Red Cross
    • Registered Articles
    • Relationships
    • Remediation
    • Repetitive Behavior
    • Repetitive behaviors
    • Research
    • Research Update
    • Research Updates
    • Respectful Care
    • retention
    • Retirement
    • Risk
    • Risk Management
    • Risperidone
    • Ritalin
    • rTMS
    • safety
    • Saffron
    • Saphris
    • Schizoaffective disorder
    • Schizophrenia
    • School Refusal
    • ScreeninGeg
    • Seasonal Affective Disorder
    • Secuado
    • Self-injury
    • Self-Regulation
    • Separation
    • Serotonin
    • Serotonin Specific Reuptake Inhibitors
    • Serotonin Specific Reuptake Inhibitors (SSRIs)
    • Sertraline
    • Sex Therapy
    • Sexual Dysfunction
    • Sexual Side Effects
    • Side Effects
    • Silexan
    • Skype
    • Sleep
    • Sleep Apnea
    • Sleep Disorders
    • Sleep Onset Insomnia
    • Smoking Cessation
    • Smoking Cessation Agents
    • smoking cessations
    • Social Anxiety Disorder
    • social cohesion
    • Special populations
    • SSRIs
    • Stereotypical Behavior
    • steroids
    • Stigma
    • stimulant
    • Stimulants
    • structured literacy
    • Suboxone
    • Substance Abuse
    • Substance Abuse
    • Substance Use
    • Substance Use Disorder
    • Substance use disorders
    • Suicidality
    • Suicide
    • Suvorexant
    • Swallowing
    • Symptom Assessment
    • Symptom Management
    • Systematic review
    • Tags
    • Tardive dyskinesia
    • Technology
    • Teen
    • teens
    • Telehealth
    • Telemed
    • Telemedicine
    • Telepsychiatry
    • test cme quiz
    • TFCBT
    • TGD
    • Therapy during medication appointment
    • Therapy with Med Management
    • TMS
    • Tobacco
    • tobacco research
    • Tobacco use disorder
    • Toxic Stress
    • Transcranial Magnetic Stimulation
    • Transdermal
    • Transgender
    • Translator
    • Trauma
    • Trauma Informed Care
    • Traumatic Brain Injury (TBI)
    • Trazodone
    • treatment
    • treatment pediatric
    • Treatment planning
    • Treatment-Resistant Depression
    • Trigeminal Nerve Stimulation
    • Trintellix
    • Understanding Psychiatric Research
    • Valbenazine
    • Vaping
    • Varenicline
    • Venlafaxine
    • videogaming addiction
    • Violence
    • Vitamin B6
    • Vitamin D
    • Vitamin E
    • VMAT2 Inhibitors
    • Vortioxetine
    • Vyleesi
    • Wakix
    • Weed
    • Weight gain
    • Weight Loss Medications
    • Wellbutrin
    • Whole Genome Sequencing
    • Wilderness Therapy Programs
    • Withdrawal
    • Women's Issues in Psychiatry
    • Women’s Issues in Psychiatry
    • Working With Families
    • Youth
  • HOME
  • STORE
  • CME CENTER
  • Blog
  • Podcast
  • NEWSLETTERS
    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
  • Archive
  • Archive
  • Archive
  • Archive
  • The Carlat Psychiatry Report
  • Esketamine (January)
  • Getting Uncomfortable with Esketamine

Getting Uncomfortable with Esketamine

The Carlat Psychiatry Report, Volume 18, Number 1, January 2020
https://www.thecarlatreport.com/newsletter-issue/tcprv18n1/

From The Carlat Psychiatry Report, January 2020, Esketamine

Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Topics: Antidepressant Augmentation | Antidepressants | Brain Devices | Depression | Depressive Disorder | ECT | Esketamine | Free Articles | Ketamine | Neurotoxicity | Novel Medications | rTMS | Suicidality | TMS | Transcranial Magnetic Stimulation | Treatment-Resistant Depression

Print Friendly, PDF & Email

Nolan Williams, MDNolan Williams, MD

Director of the Brain Stimulation Lab and Interventional Psychiatry Clinical Research Program; Assistant Professor of Psychiatry at Stanford University, CA.

Dr. Williams has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Esketamine (Spravato) was approved for treatment-resistant depression in 2019. In this interview, Dr. Williams (who has no relationship with Janssen Pharmaceuticals, Inc) addresses some lingering doubts that have been raised about the medicine.

TCPR: Where does esketamine fit in the list of interventional therapies for depression, like repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT)?
Dr. Williams: For my practice, right now ketamine and esketamine have two roles. One is for people who don’t respond to conventional rTMS—that is, rTMS with the FDA-approved methods—and either cannot or don’t want to try a course of ECT. About half of people who try conventional rTMS don’t benefit from it, so this is a fair number of people we’re talking about. The second is in emergency settings, where there’s a need for rapid relief of suicidality. For example, it might be useful with a patient who needs a sitter in the ER because of severe suicidal urges.

TCPR: How is esketamine different from ketamine?
Dr. Williams: Ketamine is made up of 2 isomers: (R)-ketamine (aka arketamine) and (S)-ketamine (aka esketamine). In this interview, I’ll use the phrase “ketamine/esketamine” when referring to both compounds. These are like right- and left-handed scissors: They look the same, but if you’re right handed and have ever tried to use left-handed scissors, you know they’re not. So we can’t completely translate the ketamine findings to esketamine, especially since there’s evidence that the other isomer—arketamine—may be the more potent one. In animal models of depression, arketamine has more potent and longer-lasting antidepressant effects, less rewarding effects, less neurotoxicity, and fewer side effects (Yang C et al, Transl Psychiatry 2015;5(9):e632). It’s too early to say how ketamine and esketamine compare clinically, but a head-to-head study is underway that will shed light on that (Correia-Melo FS et al, Medicine (Baltimore) 2018;97(38):e12414). Ketamine also has an active metabolite—norketamine—so it’s a complex drug.

TCPR: Is anyone developing arketamine for depression?
Dr. Williams: Yes. Perception, a Japanese pharmaceutical company, owns the patent and just started clinical trials in 2019. Janssen owns the esketamine patent, and the patent for ketamine is long expired, which is why these companies are pursuing the isomers.

TCPR: You alluded to some risks with esketamine. What would steer you away from it?
Dr. Williams: Ketamine/esketamine may have an abuse liability. There have been cases where patients get exposed to ketamine in an office setting and then start to order it off the internet. One academic center even shut down its ketamine program because of concerns about drug-seeking behavior (Newport DJ et al, Depress Anxiety 2016;33(8):685–688). These problems were not reported in the esketamine trial, but the investigators screened out the kinds of patients who are at risk for abuse. On balance, ketamine has some promising data as a treatment for addictions, like cocaine and alcohol (Dakwar E et al, Mol Psychiatry 2017;22(1):76–81). So this could go either way.

TCPR: And I guess that abuse potential is greater when we move toward long-term use.
Dr. Williams: That is possible, although more studies are necessary. That’s why I’m more comfortable with single-dose treatment of IV ketamine, like the way it might be used in the emergency room for suicidality. That’s analogous to single-dose opioid administration for acute pain: If someone breaks their leg, they go to the ER and they’ll probably get an opiate, but that one-time use is unlikely to lead to addiction. We also have more data on the one-time use because that’s how most of the ketamine studies were done.

TCPR: What if the patient is discharged from the emergency room? Could the suicidality return when the dose wears off in a few days?
Dr. Williams: You’d want that patient followed closely like in a partial hospital program or even a ketamine/esketamine treatment center. We deal with the same issue with hospitalization. Many patients are hospitalized for 3 days, or even 1 day, and discharged as soon as their suicidal thinking resolves. Those first few months after hospital discharge are a high-risk period for suicide. The question you’re raising is how long the benefits of single-dose IV ketamine or intranasal esketamine will last. A separate issue is whether there’s a withdrawal phenomenon when ketamine/esketamine wears off. I’m not so worried about that after one dose, but it is a concern in someone who has been taking ketamine/esketamine regularly for weeks or months.

TCPR: What do we know about esketamine withdrawal?
Dr. Williams: There’s a possibility that patients could become more suicidal after the drug is discontinued. We don’t know this for sure, but there’s a signal in the FDA-registration studies. It wasn’t statistically significant, so the drug got approved, but there were 6 deaths in the study, and this occurred after the open-label esketamine phase, so they had all been getting active treatment. Three of them were definite suicides, and these suicides occurred after their last esketamine dose: 4 days, 12 days, and 20 days after (www.fda.gov/media/121376/download). The FDA concluded that the deaths may have been due to the severity of the depression rather than the drug. However, we don’t see suicides with that kind of frequency in studies of rTMS or ECT that enroll a similar population. Furthermore, the patients who died by suicide had no signs of suicidality in detailed assessments done during the study, which suggests it may have come on during the withdrawal period.

TCPR: You’re suggesting that a drug-withdrawal effect might be behind those suicides. Do we know anything about the mechanism of action there?
Dr. Williams: Yes. We had a surprising finding last year with IV ketamine that might explain it. Our group showed that ketamine’s antidepressant effects are cancelled when you block opioid receptors with the opioid antagonist naltrexone, which means that ketamine probably has direct or indirect opioid properties (see TCPR, June/July 2019). Now, does that mean that there’s an opioid-like withdrawal when esketamine is stopped? We don’t know, but it’s possible. Ketamine also has glutamatergic effects on the NMDA receptor, but I don’t think that NMDA withdrawal would cause a problem. Otherwise we’d be seeing suicidality after patients stop memantine (Namenda).

TCPR: Sounds like more research is needed there, but it’s concerning.
Dr. Williams: Yes. We just received a grant from the American Suicide Foundation to investigate whether buprenorphine can prevent this problem and extend IV ketamine’s antidepressant effects after it is stopped. Like IV ketamine, buprenorphine has positive studies in treatment-resistant depression and in suicidality, but there’s no known risk or even a signal of suicide during its withdrawal (see TCPR, February 2019).

TCPR: Does it concern you that we haven’t found anything to prevent depressive relapse after a course of ketamine/esketamine?
Dr. Williams: Yes. So far the only thing that works is more ketamine/esketamine, which raises questions about potential tolerance, withdrawal, and addiction. Again, we don’t know that those things are happening; we just don’t have enough studies to rule them out. Riluzole was tried as a continuation agent, which like ketamine has glutamatergic effects, but it did not work (Mathew SJ et al, Int J Neuropsychopharmacol 2010;13(1):71–82). So it will be interesting to see if going through the opioid receptor continues the effects.

TCPR: Relapse is a problem after ECT as well. What can we do there?
Dr. Williams: ECT has a rich literature on this, and there’s good evidence that nortriptyline or venlafaxine can prevent episodes after a course of ECT. Lithium can also work, either alone or as antidepressant augmentation. Another strategy is to start an antidepressant that the patient responded to in the past and use that for prevention (Gill SP et al, J ECT 2019;35(1):14–20). Most patients do require maintenance ECT, at least temporarily. Those booster sessions are usually given 1–4 times a month and can be slowly tapered.

TCPR: What are the relapse rates after rTMS?
Dr. Williams: A typical course of rTMS is 5 treatments a week for 6 weeks. Each treatment takes 30–60 minutes. Afterwards, about two-thirds of patients remain well for up to 6 months without any booster sessions. If we add in booster sessions, the rate of sustained benefits goes up to 85%–90%. So rTMS appears to be more durable than esketamine, which requires booster treatments to keep it working. Also, keep in mind esketamine is an antidepressant augmentation strategy, so the patients remained on an antidepressant after stopping it. In the case of rTMS, some of the patients who stayed well were not taking any antidepressants.

TCPR: So from a long-term perspective, rTMS seems better. What about in the short term?
Dr. Williams: Ketamine and esketamine’s main advantage is that they can work quickly, within hours, which is why it has a role in the ER. rTMS takes 4–6 weeks to work. Otherwise, rTMS and ketamine have comparable remission rates. They haven’t been compared head to head, but both have remission rates of 20%–30%. ECT is the one that shines here. A recent meta-analysis estimated the remission rate on ECT at 48%. So ECT wins for efficacy, conventional rTMS wins for safety and tolerability, and esketamine wins for speed.

Table: Interventional Therapies for Depression

Table: Interventional Therapies for Depression

Click To View Full-Size PDF.

TCPR: So for now, if patients respond to esketamine or ketamine, they’re likely to require continuation treatments. What are ketamine’s long-term risks?
Dr. Williams: The biggest one is bladder inflammation or cystitis, which has been seen in people who are addicted to ketamine. It is unclear if this is a risk with therapeutic doses of esketamine or IV ketamine, and it may in fact not be. That was first reported in people who were abusing ketamine in Malaysia, and it’s likely they were taking much higher doses than what we use clinically (Lee P et al, Malays Fam Physician 2009;4(1):15–18). Since those reports came out, they’ve clarified the mechanism a bit, and it seems that ketamine abuse can lead to cellular death in the bladder and fibrotic changes in the nerves that innervate the bladder. It’s a significant problem; about 50% of ketamine abusers are affected (Jhang JF et al, Neurourol Urodyn 2019;38(8):2303–2310).

TCPR: That explains the song about ketamine by Trampolene: “Your mind might be fine, but your bladder is shredded.” Is the mind really fine after long-term ketamine use?
Dr. Williams: Not if it’s abused. Ketamine has the potential to be neurotoxic or neuroprotective, and it probably depends on the frequency of use. Long-term ketamine abuse has been associated with cognitive problems and loss of brain tissue in the frontal lobes and left temporoparietal regions (Liao Y et al, Brain 2010;133(7):2115–2122). The effect is likely due to ketamine because it is dose dependent, and it’s been replicated in animal studies with careful controls. On the neuroprotective side, ketamine does increase brain-derived neurotrophic factor (BDNF). It may be that a bit of ketamine is fine and a lot is not. There have been no reports of neurotoxicity with clinical use of ketamine and esketamine, although we haven’t really been looking for that.

TCPR: You’ve pointed out a lot of gaps in our knowledge about esketamine. What type of research needs to be done?
Dr. Williams: I would love to see a head-to-head trial of esketamine and conventional rTMS. If esketamine were to beat conventional rTMS in long-term safety and efficacy, that would likely change minds about its use.

TCPR: Thank you for your time, Dr. Williams.

Listen to this discussion in this episode of The Carlat Psychiatry Podcast.

Suggested Articles

  • Pharmacogenetics: Not Quite Ready for Prime Time? March 12, 2021 Genetic testing can tell whether a patient has an identifiable disorder, offering relief to families…
  • Managing Video Gaming in Children and Teens October 30, 2020 So many families struggle with videogaming addiction and other overuse of electronics, maybe more so…

Powered by Contextual Related Posts

Share this page!
Subscribe
Register for free content

Register For Free Articles

Register to receive free email newsletters with concise, practical advice for busy clinicians. You will also have access to select article content on the website and you will receive notifications of new books and special discount offers.




Courses and Book CME
Psychiatry Practice Boosters, Third Edition (2021)
The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)
2021 Carlat Psychiatry Report Self-Assessment Course
2020 Carlat Psychiatry Report Self-Assessment Course
The Child Medication Fact Book for Psychiatric Practice (2018)
Issues Archives

2021

  • Metabolism and Mental Health (April)
  • Stopping Psych Meds Part 2 (March)
  • Stopping Psych Meds Part 1 (February)
  • Mind-Gut Connection (January)

2020

  • Esketamine (January)
  • Telepsychiatry (May)
  • Mind-Gut Connection (January)
  • Practical Psychotherapy (November/December)
  • Mood and Menopause (October)
  • When to Use Lithium (September)
  • Traumatic Brain Injury (August)
  • Borderline Personality Disorder (June/July)
  • Psychopharmacology Algorithms (April)
  • Bipolar II (March)
  • Inflammation and Depression (February)

2020

  • Mood Disorders in Children and Adolescents (Oct/Nov/Dec)
  • Identity & Culture in Children and Adolescents (July/August/September)
  • Psychosis in Children and Adolescents (April/May/June)
  • ADHD in Children and Adolescents (Jan/Feb/Mar)

2020

  • Harm Reduction (January/February)
  • Substance Use in Health Professionals (March/April)
  • Alternative Treatment in Addiction (November/December)
  • Social Aspects of Addiction (September/October)
  • Opioid Use Disorder Treatment (July/August)
  • Emerging Risks for Old Medications (May/June)

2019

  • Depression (May)
  • Adult ADHD (November/December)
  • Mental Health Apps (October)
  • How to Talk about Medication (September)
  • Side Effects Part II (August)
  • Side Effects Part I (June/July)
  • Sleep (April)
  • Parenting, Pregnancy, and Prevention (March)
  • Dark and Light Therapy (February)
  • Deprescribing (January)

2018

  • Drug Metabolism (November/December)
  • Working With Transgender Patients (October)
  • Emergency Psychiatry (September)
  • Treatment-Resistant Depression (July/August)
  • Neurobiology (June)
  • Anxiety (May)
  • Neurofeedback (April)
  • Antipsychotics Update (March)
  • Working With Families (February)
  • Bipolar Disorder (January)

2017

  • PTSD (December)
  • Retirement (November)
  • Intellectual Disability (September/October)
  • Antidepressants (July/August)
  • Personality Disorders (June)
  • Dementia (May)
  • Cognitive Behavior Therapy Techniques (April)
  • Pharmacogenetics (March)
  • Treating Psychosis (February)
  • Adult ADHD (January)

2016

  • Complementary and Alternative Medicine in Psychiatry (November/December)
  • Side Effects (October)
  • Pain Management (September)
  • Medication in Pregnancy (July/August)
  • Psychoanalysis in Modern Psychiatry (June)
  • Correctional Psychiatry (May)
  • Antidepressant Roundup (April)
  • Burnout (March)
  • Private Practice (February)
  • Bipolar Disorder (January)

2015

  • Psychiatry and General Medicine (November/December)
  • Biomarkers in Psychiatry (May)
  • Telepsychiatry (October)
  • Sleep Disorders (September)
  • Interventional Psychiatry (July/August)
  • Eating Disorders (June)
  • Psychotherapy Updates (April)
  • Topics in Geriatric Psychiatry (March)
  • Antipsychotics Update (February)
  • Risk Management (January)

2014

  • Bipolar Disorder (November/December)
  • Pharmacogenetics (October)
  • Keeping up in Psychiatry (September)
  • Research in Psychiatry (July/August)
  • Marijuana (June)
  • Psychiatric Diagnosis (May)
  • Issues in Psychopharmacology (April)
  • Schizophrenia (March)
  • Women’s Psychiatry (February)
  • Ethics in Psychiatry (January)

2013

  • Military Psychiatry (December)
  • Depression (November)
  • Treatment of Dementia (October)
  • Anxiety Disorders (September)
  • Natural and Alternative Treatments in Psychiatry (July/August)
  • Autism Spectrum Disorder (June)
  • Practice Tips (May)
  • Substance Abuse (April)
  • Medicolegal Topics (March)
  • End of Life Care (February)
  • Antipsychotic Update (January)

2012

  • Screening Tools and Tips (December)
  • Medical Comorbidities (November)
  • Devices in Psychiatry (October)
  • Eating Disorders (September)
  • Bipolar Disorder (July/August)
  • Risk Management (June)
  • Antidepressant Roundup 2012 (May)
  • Gender and Sexuality (April)
  • Personality Disorders (March)
  • ADHD (February)
  • Natural Treatments in Psychiatry (January)

2011

  • Electronic Medical Records (December)
  • Insomnia (November)
  • Psychotherapy (October)
  • Alcoholism (September)
  • Anxiety Disorders (July/August)
  • Schizophrenia (June)
  • Managing Side Effects (May)
  • Antidepressant Roundup 2011 (April)
  • DSM-5 and Diagnostic Issues (March)
  • Drug-Drug Interactions (February)
  • Bipolar Disorder (January)

2010

  • Hospital Psychiatry (December)
  • Psychiatric Medication in Pregnancy (November)
  • Maintenance of Certification (October)
  • The Neuroscience of Psychotherapy (September)
  • Treatment of Depression (July/August)
  • Email and the Internet in Psychiatry (June)
  • Substance Abuse (May)
  • The Diagnosis and Treatment of Dementia (April)
  • Ethics in Psychiatry (March)
  • Natural Treatments in Psychiatry (February)
  • ADHD (January)

2009

  • Treating Schizophrenia (December)
  • Treatment for Anxiety Disorders (November)
  • The Latest on Antidepressants (October)
  • Topics in Neuropsychiatry (September)
  • The Interface of Medicine and Psychiatry (July/August)
  • Generic Medications in Psychiatry (June)
  • The Treatment of Eating Disorders (May)
  • Healthcare Policy and Psychiatry (April)
  • Antipsychotic Roundup 2009 (March)
  • Psychiatric Medication in Pregnancy and Lactation (February)
  • Transcranial Magnetic Stimulation (January)

2008

  • Treating Fibromyalgia and Pain in Psychiatry (December)
  • Issues in Child Psychiatry (November)
  • Improving Psychiatric Practice (October)
  • Treating Personality Disorders (September)
  • Bipolar Disorder (July/August)
  • Antipsychotic Roundup 2008 (June)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Neuropsychological Testing (May)
  • Psychiatric Medications: Effects and Side Effects (April)
  • Update on Substance Abuse (March)
  • Anticonvulsants in Psychiatry (February)
  • Brain Devices in Psychiatry (January)

2007

  • The Treatment of Insomnia (December)
  • Avoiding Malpractice in Psychiatry (November)
  • Update on Eating Disorders (October)
  • Complex Psychopharmacology (September)
  • Laboratory Testing in Psychiatry (August)
  • Psychotherapy in Psychiatry (July)
  • Posttraumatic Stress Disorder (June)
  • Topics in Geriatric Psychiatry 2007 (May)
  • Pregnancy and Menopause in Psychiatry (Apil)
  • Antipsychotic Roundup 2007 (March)
  • Understanding Psychiatric Research (February)
  • Antidepressant Round-up 2007 (January)

2006

  • Technology and Psychiatric Practice (December)
  • The Use of MAOIs (November)
  • Medication Treatment of Depression (January)
  • Seasonal Affective Disorder (October)
  • Treatment of ADHD (September)
  • Topics in Bipolar Disorder (August)
  • Neurotransmitters in Psychiatry (July)
  • Treating Substance Abuse (June)
  • The STAR*D Antidepressant Trial (May)
  • Natural Treatments in Psychiatry (April)
  • Medication Treatment of Anxiety (March)
  • Panic Disorder: Making Treatment Work (March)
  • Antipsychotic Roundup 2006 (February)
  • Antidepressant Roundup 2006 (January)

2005

  • Self-Help Books and Psychiatry (December)
  • Genetics and Psychiatry (November)
  • Pregnancy and Psychiatric Treatment (October)
  • Benzodiazepines and Hypnotics in Psychiatry (September)
  • Geriatric Psychiatry Update (August)
  • Chart Documentation in Psychiatry (July)
  • The Treatment of Bipolar Disorder (June)
  • Weight Loss and Smoking Cessation in Psychiatry (May)
  • Treating ADHD (April)
  • Drug Industry Influence in Psychiatry (March)
  • Atypical Antipsychotics 2005 (February)
  • Antidepressant Roundup 2005 (January)

2004

  • Sexual Dysfunction (December)
  • Suicide Prevention (November)
  • To Sleep, To Awake (October)
  • Women’s Issues in Psychiatry (September)
  • OCD: An Update (August)
  • Chronic Pain and Psychiatry (July)
  • Neuroimaging in Psychiatry (June)
  • Natural Medications in Psychiatry (May)
  • Posttraumatic Stress Disorder (April)
  • Treatment of Alcoholism (March)
  • Battle of the Atypicals (February)
  • Antidepressant Roundup, 2004 (January)

2003

  • Research Methods in Psychiatry (December)
  • Antidepressants in Children (November)
  • The Treatment of Dementia (October)
  • Bipolar Disorder, Part II: The Novel Anticonvulsants (September)
  • Bipolar Disorder: The Basics (August)
  • Drug-Drug Interactions in Psychiatry (July)
  • Managing Antidepressant Side Effects (June)
  • Antidepressants in Pregnancy and Lactation (May)
  • ADHD: Medication Options (April)
  • Panic Disorder: Making Treatment Work (March)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Medication Treatment of Depression (January)

2019

  • Autism in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (May/June/July/August)
  • Substance Use in Children and Adolescents (September/October)
  • Trauma in Children and Adolescents (March/April)
  • Anxiety in Children and Adolescents (January/February)

2018

  • Psychotropic Risks in Children and Adolescents (May/June)
  • ADHD in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (September/October)
  • Autism in Children and Adolescents (July/August)
  • Anxiety in Children and Adolescents (March/April)
  • Suicide in Children and Adolescents (January/February)

2017

  • Adolescents (November/December)
  • ADHD in Children and Adolescents (September/October)
  • Psychosis in Children and Adolescents (August)
  • PANDAS, PANS, and Related Disorders (June/July)
  • Marijuana in Children and Adolescents (May)
  • Tourette’s and Other Tic Disorders in Children and Adolescents (March/April)
  • Autism in Children and Adolescents (January/February)

2016

  • Gender Dysphoria in Children and Adolescents (November/December)
  • Technology Issues With Children and Adolescents (September/October)
  • Mood Dysregulation in Children and Adolescents (July/August)
  • Eating Disorders in Children and Adolescents (May/June)
  • Conduct Disorder in Children and Adolescents (April)
  • Sleep Disorders in Children and Adolescents (March)
  • ADHD in Children and Adolescents (January/February)

2015

  • Antidepressant Use in Children (November/December)
  • Foster Care and Child Psychiatry (September/October)
  • Autism (July/August)
  • Trauma (May/June)
  • Anxiety Disorders (April)
  • Schools and Psychiatry (March)
  • Emergency Psychiatry in Children (January/February)

2014

  • Antipsychotics in Children (December)
  • ADHD (November)
  • Gender and Sexuality (September/October)
  • Psychotic Symptoms (Summer)
  • Medication Side Effects (May)
  • Food and Mood (April)
  • Learning and Developmental Disabilities (February)

2013

  • Complex Practice Issues (December)
  • Diet and Nutrition (November)
  • Child Psychiatry in DSM-5 (August/September)
  • Medication Side Effects and Interactions (June/July)
  • Problematic Technology (March/April)
  • Autism Spectrum Disorders (January/February)

2012

  • Bipolar Disorder (December)
  • Substance Abuse (October/November)
  • Transitional Age Youth (July/August)
  • Rating Scales (May/June)
  • Eating Disorders (March/April)
  • Behavioral Disorders (February)

2011

  • Treatment of Anxiety Disorders (December)
  • Trauma (November)
  • Bullying and School Issues (October)
  • Hidden Medical Disorders (August)
  • OCD and Tic Disorders (June)
  • Suicide and Non-Suicidal Self Injury (April)
  • Sleep Disorders (March)
  • ADHD (January)

2010

  • Use of Antipsychotics in Children and Adolescents (December)
  • Learning and Developmental Disabilities (October)
  • Major Depression (September)
  • Treating Children and Families (July)
  • The Explosive Child (May)

2019

  • Dual Diagnosis in Addiction Medicine (May/June)
  • Medical Issues in Addiction Practice (November/December)
  • Alcohol Addiction (September/October)
  • Legal Issues in Addiction Medicine (July/August)
  • Traumatic Brain Injury and Addiction (March/April)
  • Board Certification in Addiction Medicine (January/February)

2018

  • Opioid Addiction (November/December)
  • Addiction in Older Adults (October)
  • Sleep Disorders and Addiction (September)
  • Adolescent Addiction (July/August)
  • Pain and Addiction (May/June)
  • Cannabis and Addiction (March/April)
  • Stigma and Addiction (January/February)

2017

  • Pregnancy and Addiction (November/December)
  • Detox (Sepember/October)
  • Dual Diagnosis (August)
  • Alternatives to 12-Step Programs (June/July)
  • Recovery (May)
  • Psychiatric Uses of Street Drugs (March/April)
  • Sex Addiction (January/February)

2016

  • Prescription Drug Monitoring Programs (PDMPs) (November/December)
  • Addiction in Health Care Professionals (September/October)
  • Dialectical Behavior Therapy in Addiction (August)
  • Motivational Interviewing (June/July)
  • Benzodiazepines (May)
  • Opioid Addiction (March/April)
  • Families and Substance Abuse (January/February)

2015

  • The Twelve Steps (November/December)
  • Designer Drugs (September/October)
  • Residential Treatment Programs Decoded (July/August)
  • Nicotine and E-Cigarettes (June)
  • Drug Screening (April/May)
  • Integrating Therapy and Medications for Alcoholism (March)
  • Detoxification Protocols (January/February)

2014

  • Behavioral Addictions (December)
  • Risk and Reimbursement (November)
  • Stimulant Abuse (September/October)
  • Self-Help Programs (June)
  • Opioid Addiction (May)
  • Coping with Bad Outcomes (March)
  • Change Management in Addiction Treatment (January/February)

2013

  • Cocaine Addiction (December)
  • Relapse Prevention (November)
  • Cannabis Addiction (August/September)
  • Addiction in DSM-5 (June/July)
Editor-in-Chief

Chris Aiken, MD

Dr. Aiken is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice.

Full Editorial Information

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Subscriptions
  • Books
  • Online Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Child Psychiatry Report
  • The Carlat Hospital Psychiatry Report

Contact

  • info@thecarlatreport.com
  • 866-348-9279
  • PO Box 626, Newburyport MA 01950

Follow Us

© 2021 Carlat Publishing, LLC and Affiliates, All Rights Reserved.

Please see our Privacy Policy and the Hardware/Software Requirements to view our website.

×